Biotech proved a surprisingly bright spot in 2022’s startup correction
While not totally immune to 2022’s market correction, biotech fundraising proved to be more resilient than other sectors.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
